Labcorp Drug Development Radioanalysis Case Study

A leading biotechnology client contracted with Labcorp for a human absorption, metabolism and excretion (AME) study using 14C to determine the excretory pathway and metabolite identification and potential enterohepatic recycling. The Labcorp CRU team in Madison, Wisconsin, gave subjects doses of the radiolabeled drug, then collected samples, analyzed data and reported results each day of the trial - with a target threshold of 90 percent recovery. The sponsor would compare the clinical study results to the preclinical data to make decisions regarding the drug's further development.